Oral Benzofuran Formulations Using SDDs for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cannabinoid receptor modulating compounds face challenges with solubility and bioavailability when administered orally due to their hydrophobic nature, leading to incomplete absorption and first-pass metabolism, which affects their therapeutic efficacy.
Innovation Solution
Development of novel oral formulations using spray dried dispersions (SDDs) comprising benzofuran compounds and hydroxypropyl methylcellulose acetate succinate (HPMCAS-M) to enhance solubility and bioavailability, allowing for effective modulation of CB1 and CB2 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral cannabinoid formulations are administered, then systemic delivery is achieved, but first-pass metabolism causes unpredictable and non-linear pharmacokinetics
Solution Approach 1:
The patent uses a self-emulsifying drug delivery system (SEDDS) as an intermediary between the cannabinoid drug and the gastrointestinal tract. This SEDDS formulation pre-forms micelles that protect the drug from first-pass metabolism and enable predictable absorption, resolving the contradiction between achieving systemic delivery and avoiding unpredictable metabolic effects.
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by using specific oil phases, surfactants, and co-surfactants in defined ratios. This creates a self-emulsifying system that transforms the drug's delivery characteristics from unpredictable first-pass metabolism to controlled, linear pharmacokinetics with predictable absorption rates.
2Reliability
If high potency cannabinoid formulations are used, then therapeutic efficacy is improved, but gastrointestinal irritation and vomiting are exacerbated
Solution Approach 1:
The SEDDS formulation acts as a protective intermediary that encapsulates high potency cannabinoids. The surfactant and co-surfactant mixture creates micelles that shield the gastrointestinal mucosa from direct contact with irritating cannabinoid compounds while still allowing controlled absorption for therapeutic effect.
Solution Approach 2:
The patent modifies the formulation parameters by incorporating specific ratios of surfactants and co-surfactants that reduce surface tension and improve wetting characteristics. This creates a gentler formulation that maintains high potency therapeutic effects while reducing gastrointestinal irritation and vomiting side effects.
3Adaptability or versatility
If cannabinoid formulations are administered to pediatric or geriatric patients, then treatment coverage is expanded, but dosing accuracy becomes difficult due to variable absorption
Solution Approach 1:
The SEDDS formulation provides a universal delivery system that works across different patient populations including pediatrics and geriatrics. The self-emulsifying mechanism and micelle formation are physiological processes that function consistently across age groups, enabling accurate dosing and predictable pharmacokinetics regardless of patient age or metabolic variability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations improve oral bioavailability and therapeutic efficacy by ensuring complete dissolution and absorption of cannabinoid receptor modulators, enabling effective treatment of cannabinoid receptor-mediated diseases and disorders.
Implementation Method 1
self-emulsifying drug delivery system
Implementation Method 2
pharmaceutically acceptable surfactant and co-surfactant mixture
Implementation Method 3
dissolution and absorption characteristics
Implementation Method 4
dissolution and absorption characteristics
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Oral formulations of benzofuran compounds which modulate cannabinoid receptors are presented. Methods of using these formulations for treatment of cannabinoid receptor-mediated disease, including neuropathic pain and addition, are also described.